SCHEMBL3885451

SCHEMBL3885451

CCCCCCCC(=O)C=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.59
CES2 O00748 4/20 0.56
CES1 P23141 4/20 0.56
GPR84 Q9NQS5 7/20 0.54
PPARG P37231 7/20 0.54
PPARD Q03181 7/20 0.54
PPARA Q07869 7/20 0.54
HDAC11 Q96DB2 5/20 0.54
TSHR P16473 5/20 0.54
PTPN1 P18031 3/20 0.54
ALDH1A1 P00352 3/20 0.54
TLR2 O60603 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
FABP4 P15090 2/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
SLC22A8 Q8TCC7 1/20 0.54
MEN1 O00255 1/20 0.54
ESR1 P03372 1/20 0.54
ALOX15 P16050 1/20 0.54
PDE4A P27815 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10716756 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL10821138 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL3172765 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL10582668 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL2567832 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL7717417 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL7065108 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL11159859 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL769596 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG
SCHEMBL9290892 1.00 TRPA1 (0.59) TRPA1CES2CES1GPR84PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111773130-A Hydroxypropyl tetrahydropyrane triol compound and preparation method and application thereof 贝乐科(上海)生物科技有限公司 2020-10-16 CN claimed
WO-1996006102-A1 PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDE MIXTURES CIBA-GEIGY AG (CH) 1996-02-29 WO claimed
CN-119367549-A Hydrophilic linkers and conjugates thereof 芬兰吉利科斯有限公司 2025-01-28 CN disclosed
CN-111065416-B Hydrophilic linkers and conjugates thereof 芬兰吉利科斯有限公司 2024-09-13 CN disclosed
CN-118147152-A Aptamer for detecting Neu5Gc and method for detecting Neu5Gc based on AP-Cas12a 吉林大学 2024-06-07 CN disclosed
US-20230321259-A1 GLYCOCONJUGATES AND MEDICAL USES THEREOF REMAB THERAPEUTICS SL (ES) 2023-10-12 US disclosed
CN-116437966-A Glycoconjugates and medical uses thereof 瑞马布治疗有限公司 2023-07-14 CN disclosed
CN-113748212-B Enzymatic process for preparing GDP-fucose 马克斯·普朗克科学促进学会 2023-04-25 CN disclosed
CN-115944643-A Application of sialic acid in preparing anti-osteoporosis medicine and food 江南大学附属医院 2023-04-11 CN disclosed
CN-114641577-A Enzymatic process for the preparation of UDP-galactose 马克斯·普朗克科学促进学会 2022-06-17 CN disclosed
CN-114630911-A Enzymatic process for the preparation of UDP-GlcNAc 马克斯·普朗克科学促进学会 2022-06-14 CN disclosed
WO-1998047915-A1 NEOGLYCOPROTEINS NOVARTIS AG (CH) 1998-10-29 WO disclosed
EP-0866802-A1 MULTIVALENT POLYMERS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE FOR PREPARING BIOLOGICALLY ACTIVE COMPOUNDS. Novartis AG (CH) 1998-09-30 EP disclosed
EP-0801684-A1 PROCESS FOR THE COMPLETE REMOVAL OF PROTECTIVE GROUPS ON NUCLEOSIDE DIPHOSPHATE AND TRIPHOSPHATE SUGARS Novartis AG (CH) 1997-10-22 EP disclosed
WO-1997019105-A1 MULTIVALENT POLYMERS, PROCESSES FOR THEIR PREPARATION, AND THEIR USE FOR PREPARING BIOLOGICALLY ACTIVE COMPOUNDS. NOVARTIS AG (CH) 1997-05-29 WO disclosed
US-5610016-A REACTING A GLYOXAL DERIVATIVE, CHEMILUMINESCENCE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1997-03-11 US disclosed
US-5569786-A ANTICARCINOGENIC AGENTS, LEUKEMIA ARIZONA BOARD OF REGENTS ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 1996-10-29 US disclosed
WO-1996024683-A1 PROCESS FOR THE COMPLETE REMOVAL OF PROTECTIVE GROUPS ON NUCLEOSIDE DIPHOSPHATE AND TRIPHOSPHATE SUGARS NOVARTIS AG (CH) 1996-08-15 WO disclosed
WO-1996006102-A1 PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDE MIXTURES CIBA-GEIGY AG (CH) 1996-02-29 WO disclosed
EP-0675360-A2 Method for measuring adenyl group containing substances using heteropoly acid MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1995-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321259-A1 GLYCOCONJUGATES AND MEDICAL USES THEREOF B3GAT3, FUT5, FUT6 TRPA1 4573/4885CES2 1111/4885CES1 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.